Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | PSIP1 | O75475 | 1/20 | 0.55 |
| ▸ | F2 | P00734 | 3/20 | 0.54 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.54 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.54 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.54 |
| ▸ | CA1 | P00915 | 1/20 | 0.54 |
| ▸ | CA2 | P00918 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | IL1RN | P18510 | 1/20 | 0.53 |
| ▸ | MEP1B | Q16820 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 4/20 | 0.51 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29453097 | 1.00 | CYP2C19 (0.55) | CYP2C19PSIP1F2PRSS1PRSS2 | |
| SCHEMBL4248338 | 0.88 | CYP2C19 (0.55) | CYP2C19F2PRSS1PRSS2PRSS3 | |
| SCHEMBL27961684 | 0.87 | PSIP1 (0.52) | PSIP1ALDH1A1LMNA | |
| SCHEMBL11311538 | 0.85 | CYP2C19 (0.49) | CYP2C19F2PRSS1PRSS2PRSS3 | |
| SCHEMBL4416606 | 0.84 | ALDH1A1 (0.56) | CYP2C19F2PRSS1PRSS2PRSS3 | |
| SCHEMBL29503157 | 0.84 | GAA (0.53) | PSIP1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL11196949 | 0.84 | GAA (0.53) | PSIP1F2PRSS1PRSS2PRSS3 | |
| SCHEMBL20306074 | 0.84 | PSIP1 (0.48) | PSIP1CA1CA2ALDH1A1LMNA | |
| SCHEMBL29245371 | 0.84 | F2 (0.57) | CYP2C19F2PRSS1PRSS2PRSS3 | |
| SCHEMBL19071740 | 0.84 | CYP2C19 (0.54) | CYP2C19F2PRSS1PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3551633-B1 | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | LEO PHARMA AS (DK) | 2021-03-31 | — | — | EP | claimed |
| CN-111108109-A | Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitors | 利奥制药有限公司 | 2020-05-05 | — | — | CN | claimed |
| CN-110099905-A | SUBSTITUTED PYRAZOLOAZEPIN-8-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-06 | — | — | CN | claimed |
| CN-110088108-A | SUBSTITUTED PYRAZOLOAZEPIN-4-ONES AND THEIR USE AS PHOSPHODIESTERASE INHIBITORS | 利奥制药有限公司 | 2019-08-02 | — | — | CN | claimed |
| WO-2025059562-A1 | SUBSTITUTED AMINOPYRIDINE COMPOUNDS AND METHODS OF TREATING DISEASE USING SAME | ATAVISTIK BIO, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| EP-3458447-B1 | PIPERAZINYL METHANONE NAAA INHIBITORS | UNIV CALIFORNIA (US) | 2023-11-29 | — | — | EP | disclosed |
| CN-109476616-B | Piperazinyl methanone NAAA inhibitors | 加利福尼亚大学董事会 | 2023-10-13 | — | — | CN | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | AMGEN INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2020-07-16 | — | — | US | disclosed |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | CYTOKINETICS, INC. | 2020-07-16 | — | — | US | disclosed |
| EP-1493743-A1 | Substituted bipiperidine intermediates and derivatives thereof | AstraZeneca AB (SE) | 2005-01-05 | — | — | EP | disclosed |
| US-20040014783-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-22 | — | — | US | disclosed |
| US-20040006080-A1 | Chemical compounds | ASTRAZENECA AB, A SWEDEN CORPORATION | 2004-01-08 | — | — | US | disclosed |
| CN-1433411-A | Compound (I) | ASTRAZENECA AB (SE) | 2003-07-30 | — | — | CN | disclosed |
| US-6525070-B2 | For therapy of chemokine (such as CCR3) or H1 mediated disease state | ASTRAZENECA AB (SE) | 2003-02-25 | — | — | US | disclosed |
| EP-1274701-A1 | CHEMICAL COMPOUNDS | AstraZeneca AB (SE) | 2003-01-15 | — | — | EP | disclosed |
| US-20020077337-A1 | Chemical compounds | ASTRAZENECA AB (SE) | 2002-06-20 | — | — | US | disclosed |
| WO-2001077101-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2001-10-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | CYP2C19 4278/4885PSIP1 2557/4885F2 4577/4885 |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | CYP2C19 4278/4885PSIP1 2557/4885F2 4577/4885 |
| US-20020077337-A1 | Chemical compounds | CCR3, CCR1, CCR4 | CYP2C19 1230/4885PSIP1 3476/4885F2 780/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | CYP2C19 4278/4885PSIP1 2557/4885F2 4577/4885 |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | CYP2C19 4278/4885PSIP1 2557/4885F2 4577/4885 |
| US-10723720-B2 | Bisamide sarcomere activating compounds and uses therof | TNNI3, TNNT2, TNNC1 | CYP2C19 4599/4885PSIP1 2756/4885F2 2577/4885 |
| US-20040006080-A1 | Chemical compounds | CCR3, CCR1, CCR4 | CYP2C19 1230/4885PSIP1 3476/4885F2 780/4885 |
| US-20040014783-A1 | Chemical compounds | CCR3, CCR1, CCR4 | CYP2C19 1230/4885PSIP1 3476/4885F2 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.